China Resources Pharmaceutical Group Limited (03320.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	588.4B	300.0B	274.2B	270.4B	223.1B
Cost of Revenue	493.6B	250.5B	230.9B	228.4B	188.8B
Gross Profit	94.7B	49.5B	43.3B	42.4B	34.4B
Operating Expenses
R&D Expense	5.5B	3.2B	2.5B	2.7B	1.8B
SG&A Expense	63.4B	32.5B	28.3B	27.8B	19.3B
General & Admin Expense	11.7B	7.9B	7.2B	7.0B	4.9B
Selling & Marketing Expense	35.5B	24.6B	21.1B	20.8B	14.4B
Other Expenses	1.0K	—	(1.3M)	—	3.7B
Total Operating Expenses	68.9B	35.6B	30.7B	30.5B	24.9B
Cost and Expenses	562.6B	286.1B	261.3B	258.5B	213.6B
Operating Income (EBIT)	25.8B	13.9B	12.6B	13.9B	9.5B
Non-Operating
Interest Income	1.0B	524.9M	681.1M	587.7M	732.2M
Interest Expense	4.2B	2.2B	2.3B	2.4B	2.5B
Net Interest Income	(3.2B)	(1.7B)	(1.6B)	(1.8B)	(1.8B)
Other Non-Op Income/Expense	(1.3B)	(774.4M)	(931.9M)	(3.0B)	(840.1M)
Non-Operating Income (excl Interest)	(109.1M)	(177.1M)	146.8M	—	(1.3B)
EBT (Pre-Tax Income)	24.5B	13.1B	11.6B	10.9B	8.7B
Income Tax Expense	5.1B	2.4B	2.7B	2.3B	1.8B
Bottom Line
Net Income	7.8B	4.5B	3.6B	4.2B	3.6B
Earnings from Cont. Ops	19.4B	10.7B	8.9B	8.6B	6.9B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	7.7B	4.5B	3.5B	4.3B	3.1B
Per Share
Basic EPS	HK$1.23	HK$0.72	HK$0.56	HK$0.68	HK$0.55
Diluted EPS	HK$1.23	HK$0.72	HK$0.56	HK$0.68	HK$0.55
Revenue Per Share	HK$93.65	HK$47.75	HK$43.64	HK$43.04	HK$35.52
Shares
Basic Shares Outstanding	6.3B	6.3B	6.3B	6.3B	6.3B
Diluted Shares Outstanding	6.3B	6.3B	6.3B	6.3B	6.3B
Profitability Metrics
EBITDA	33.2B	17.7B	15.5B	15.4B	13.6B
D&A	7.3B	3.6B	2.7B	3.2B	2.8B
EBIT	25.9B	14.1B	12.8B	11.9B	10.8B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026